Image Credit: AFP
For all the flak the pharmaceutical industry has taken for its exorbitant pricing practices, theres no getting around the fact that its been a pretty stunning decade for medical progress.
Multiple new categories of medicines have moved from dreams and lab benches into the market and peoples lives, and investors who came along for the ride often reaped extraordinary profits. The Nasdaq Biotech Index is up 360 per cent over the last 10 years to the S&P 500s 190 per cent. And thats without mentioning the hundreds of billions of dollars in takeovers that rewarded shareholders with windfalls.
As 2020 approaches, its worth highlighting how far weve come in the past 10 years in developing new therapies and approaches to treating disease, even as politicians grapple with how to rein in health-care costs without breaking an ecosystem that incentivises the search for new discoveries.
Here are some of the decades biggest medical breakthroughs:
Cell therapies
First approved in the US two years ago, these treatments still sound like science fiction. Drugmakers harvest immune cells from patients, engineer them to hunt tumours, grow them by the millions into a living drug, and reinfuse them. Yescarta from Gilead Siences Inc. and Novartis AGs Kymriah the two treatments approved so far can put patients with deadly blood cancers into remission in some cases. At the beginning of the decade, academics were just beginning early patient tests.
Its still early days for the technology, and some issues are holding these drugs back. There are significant side effects, and the bespoke manufacturing process is expensive and time-consuming. That has contributed to a bruising price tag: Both of the approved medicines cost over $350,000 (Dh1.28 million) for a single treatment. And for now, cell therapy is mostly limited to very sick patients who have exhausted all other alternatives.
Luckily, more options are on their way. Some drugmakers are focused on different types of blood cancers. Others hope to mitigate side effects or create treatments that can be grown from donor cells to reduce expenses and speed up treatment. In the longer run, companies are targeting trickier solid tumours. Scientists wouldnt be looking so far into the future without this decades extraordinary progress.
Gene therapies
Researchers have spent years trying to figure out how to replace faulty DNA to cure genetic diseases, potentially with as little as one treatment. Scientific slip-ups and safety issues derailed a wave of initial excitement about these therapies starting in the 1990s; the first two such treatments to be approved in Europe turned out to be commercial flops.
This decade, the technology has come of age. Luxturna, a treatment developed by Spark Therapeutics Inc. for a rare eye disease, became the first gene therapy to get US approval in late 2017. Then in May came the approval of Novartis AGs Zolgensma for a deadly muscle-wasting disease. The drugs have the potential to stave off blindness and death or significant disability with a single dose, and, unsurprisingly, Big Pharma has given them a substantial financial endorsement. Roche Holding AG paid $4.7 billion to acquire Spark this year, while Novartis spent $8.7 billion in 2018 to buy Zolgensma developer Avexis Inc.
Dozens of additional therapies are in development for a variety of other conditions and should hit the market in the next few years. They offer the tantalising potential not just to cure diseases, but to replace years of wildly expensive alternative treatment. If drugmakers can resist the temptation to squeeze out every ounce of value by doing things like charging $2.1 million for Zolgensma, theres potential for these treatments to save both lives and money.
RNA revolution
The above treatments modify DNA; this group uses the bodys messaging system to turn a patients cells into a drug factory or interrupt a harmful process. Two scientists won a Nobel Prize in 2006 for discoveries related to RNA interference (RNAi), one approach to making this type of drug, showing its potential to treat difficult diseases. That prompted an enormous amount of hype and investment, but a series of clinical failures and safety issues led large drugmakers to give up on the approach. Sticking with it into this decade paid off.
Alnylam Inc. has been working since 2002 to figure out the thorny problems plaguing this class of treatments. It brought two RNAi drugs for rare diseases to the market in the past two years and has more on the way. The technology is also moving from small markets to larger ones: Novartis just paid $9.7 billion to acquire Medicines Co. for its Alnylam-developed drug that can substantially lower cholesterol with two annual treatments.
Ionis Pharmaceuticals Inc. and Biogen Inc. collaborated on Spinraza, a so-called antisense drug that became the first effective treatment for a deadly rare disease. It was approved in late 2016 and had one of the most impressive drug launches of the decade. And Moderna Therapeutics rode a wave of promising messenger RNA-based medicines to the most lucrative biotechnology IPO of all time in 2018. From pharma abandonment to multiple approvals and blockbuster sales potential in under 10 years. Not bad!
Cancer immunotherapy
Scientists had been working on ways to unleash the human immune system on cancers well before the 2010s without much luck. Checkpoint inhibitors drugs that release the brakes on the bodys defence mechanisms have since produced outstanding results in a variety of cancers and are the decades most lucrative turnaround story.
Merck got a hold of Keytruda via its 2009 acquisition of Schering-Plough, but it was far from the focus of that deal. Once Bristol-Myers Squibb & Co. produced promising results for its similar drug, Opdivo, Merck started a smart development plan that has turned Keytruda into the worlds most valuable cancer medicine. Its now available to treat more than 10 types of the disease, and has five direct competitors in the US alone. Analysts expect the category to exceed $25 billion in sales next year.
If anything, the drugs may have been too successful. Copycat efforts are pulling money that could fund more innovative research. There are thousands of trials underway attempting to extend the reach of these medicines by combining them with other drugs. Some are based more on wishful thinking than firm scientific footing. Still, the ability to shrink some previously intractable tumours is a considerable advance. If drugmakers finally figure out the right combinations and competition creates pricing pressure that boosts access, these medicines will do even more in the years to come.
Conquering hepatitis C
From a combined economic and public-health standpoint, a new group of highly effective hepatitis C medicines may outstrip just about anything else on this list so far. Cure rates for earlier treatments werent especially high; they took some time to work and had nasty side effects. The approval of Gileads Sovaldi in 2013, followed in time by successor drugs such as AbbVie Inc.s Mavyret, have made hepatitis C pretty easily curable in a matter of weeks. For Gilead, getting to market rapidly with its drug proved enormously profitable; it raked in over $40 billion in revenue in just three years.
Hepatitis C causes liver damage over time that can lead to transplants or cancer. The existence of a rapid cure is a significant long-term boon even if the initial pricing on the drugs made them, in some cases, prohibitively expensive. Sovaldi notoriously cost $1,000 per pill at launch and over $80,000 for a course of treatment. The good new is, treatments have become a lot more affordable, which should allow this class of drugs to have a broad and lasting positive health impact.
Hepatitis C is one of the relatively few markets where the drug-pricing system has worked well. As competing medicines hit the market, the effective cost of these treatments plummeted. That, in turn, made the drugs more accessible to state Medicaid programmes and prison systems, which operate on tight budgets and care for populations with higher rates of hepatitis C infection. Louisiana has pioneered the use of a Netflix model, under which the state paid an upfront fee for unlimited access to the drug. Its an arrangement that will help cure thousands of patients, and other states are likely to follow its lead.
Many of the medicines highlighted in this column have list prices in the six figures, a trend thats helped drive up Americas drug spending by more than $100 billion since 2009. Building on this decades medical advances is going to lead to even more effective medicines that will likely come with steeper prices. Id like to hope that policymakers will come up with a solution that better balances the need to reward innovation with the need to keep medicines accessible. That would really be a breakthrough.
Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care.
View post:
The medical breakthroughs of the past decade | Op-eds - Gulf News
- Understanding Menopause and its Symptoms | Menopause Treatment Options - Medriva - December 28th, 2023 [December 28th, 2023]
- Breast cancer survivor Jayne Pritchard talks alternative therapies over tea - MidlandToday - December 28th, 2023 [December 28th, 2023]
- 12 unusual ways Israelis are volunteering during the war - ISRAEL21c - December 28th, 2023 [December 28th, 2023]
- Complementary and alternative medicine - NHS - December 26th, 2022 [December 26th, 2022]
- Alternative Treatment (CAM) for MS: Types, Side Effects & Cost - December 26th, 2022 [December 26th, 2022]
- Complementary and alternative medicine | History & Facts - December 26th, 2022 [December 26th, 2022]
- Alternative medicine: Definition, examples, benefits, and risks - October 28th, 2022 [October 28th, 2022]
- Alternative Medicine: The Science Behind 10 Alternative Therapies - October 21st, 2022 [October 21st, 2022]
- Detoxification (alternative medicine) - Wikipedia - October 21st, 2022 [October 21st, 2022]
- Alternative Approaches to Mental Health and Wellbeing - Psychiatric Times - October 19th, 2022 [October 19th, 2022]
- New practice focuses on dental sleep medicine, providing an alternative for patients who use CPAP machines - PennLive - October 19th, 2022 [October 19th, 2022]
- Dr. Deepak Chopra Aligns with Plant-Based Therapeutics Company ProVEDA to Highlight Topical Pain Relief Solutions - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- True REST Float Spa Offers Free Floatation Therapy Session to Veterans - AccessWire - October 19th, 2022 [October 19th, 2022]
- Youve been told you need surgery for degenerative disc disease and stenosis of the spine. Now what? - Sonoran News - October 19th, 2022 [October 19th, 2022]
- Can you take Paxlovid and heart disease medications at the same time? - Medical News Today - October 15th, 2022 [October 15th, 2022]
- Kardashian fans think theyve unlocked Kourtneys secret to hiding her pregnancy after spotting key detai... - The US Sun - October 15th, 2022 [October 15th, 2022]
- Cabinet approves B5bn for 'Andaman International Health Center' - The Phuket News - October 15th, 2022 [October 15th, 2022]
- Eye health and dynamics of the modern world - The Citizen - October 15th, 2022 [October 15th, 2022]
- The Holistic Review on Occurrence, Biology, Diagnosis, and Treatment of Oral Squamous Cell Carcinoma - Cureus - October 15th, 2022 [October 15th, 2022]
- 10 Deeper Causes of Tinnitus, and How to Treat It - The Epoch Times - October 15th, 2022 [October 15th, 2022]
- Complementary and Alternative Medicine (CAM) - GoodTherapy - October 13th, 2022 [October 13th, 2022]
- India's alternative medicine industry grows, boosted by COVID-19 pandemic - CNA - October 13th, 2022 [October 13th, 2022]
- QC Kinetix (Charlotte) Offers Alternative Treatments for Knee Pain and Sports Injuries - Yahoo Finance - October 13th, 2022 [October 13th, 2022]
- Plant Extracts Market is expected to generate a revenue of USD 85.09 Billion by 2030, Globally, at 6.33% CAGR: Verified Market Research - Yahoo... - October 13th, 2022 [October 13th, 2022]
- Neuroplasticity Nonsense Is Full of Red Flags - Science Based Medicine - October 13th, 2022 [October 13th, 2022]
- Diabetics won't be made to pay for alternative medicines, Pharmac says - Stuff - October 13th, 2022 [October 13th, 2022]
- Lili Reinhart Becomes A Reiki Master: My Journey Into Reiki Healing Cant Be Simplified - IMDb - October 13th, 2022 [October 13th, 2022]
- The DRIPBaR is Coming to Clarksville, TN on Oct 16, 2022 - PR Web - October 13th, 2022 [October 13th, 2022]
- How Dr. Oz Boosted an Osteopath Who Became a Top Spreader of Covid Misinformation Mother Jones - Mother Jones - October 13th, 2022 [October 13th, 2022]
- World Arthritis Day: Arthritis and Women - Times of India - October 13th, 2022 [October 13th, 2022]
- What Is Alternative Medicine? - American Cancer Society - October 6th, 2022 [October 6th, 2022]
- Herbal medicine: Types, uses, and safety - Medical News Today - October 6th, 2022 [October 6th, 2022]
- WCI Health LLC, Your Alternative Health and Wellness Hub Will Be a Vendor and Presenter at Wonderland Miami by Microdose - StreetInsider.com - October 6th, 2022 [October 6th, 2022]
- The Viral Real - Journal #130 October 2022 - E-Flux - October 6th, 2022 [October 6th, 2022]
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 6th, 2022 [October 6th, 2022]
- Woman, 37, dies after herbal supplements led to liver failure: coroner - Insider - October 6th, 2022 [October 6th, 2022]
- What Is Vitiligo? All About This Unique Skin Condition That Impacts Skin Pigmentation, and How To Treat It - Parade Magazine - October 6th, 2022 [October 6th, 2022]
- Herbalist's Resource Guide to Cannabis and Other Plants That Can Prevent Cancer - PR Web - October 6th, 2022 [October 6th, 2022]
- Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Bas - Benzinga - October 6th, 2022 [October 6th, 2022]
- "Sh*t, I just want to get better. Thats what pushed me to do it, and it worked well" Chauncey Billups and other NBA stars on acupuncture -... - October 6th, 2022 [October 6th, 2022]
- People Science and Symbiome Partner to study the microbiome in the real world - Benzinga - October 6th, 2022 [October 6th, 2022]
- Bob Newhart Proves 93 Is the New 39 - Eat This, Not That - September 29th, 2022 [September 29th, 2022]
- Medical cannabis could be better alternative to opioids in managing pain - The Tribune India - September 29th, 2022 [September 29th, 2022]
- Woman killed by herbal remedies she took to treat arthritis - Evening Standard - September 29th, 2022 [September 29th, 2022]
- Get To Know The Best Natural Adderall Alternatives - Over The Counter and Non Prescription - Outlook India - September 29th, 2022 [September 29th, 2022]
- King Charles III Has a History of Promoting 'Quackery' Alternative Medicine - Newsweek - September 9th, 2022 [September 9th, 2022]
- Remedy Place: The Fashionable Social Wellness Club Where You Can Bring All Your Friends - Vogue - September 9th, 2022 [September 9th, 2022]
- Thailand heightens its healthcare hub ambition with integrative medicine - PR Newswire UK - September 9th, 2022 [September 9th, 2022]
- How bogus cancer treatments prey on the most vulnerable - Coda Story - September 9th, 2022 [September 9th, 2022]
- Management of Chronic Migraine in Children and Adolescents | PHMT - Dove Medical Press - September 9th, 2022 [September 9th, 2022]
- Mouth Taping: Is It Safe? - Health Essentials - September 9th, 2022 [September 9th, 2022]
- Queen Elizabeth: Seven things you need to know about the Queens passing - Toronto Star - September 9th, 2022 [September 9th, 2022]
- Building an Alternative Medical Economy in Response to 'Tyranny': Telehealth CEO - The Epoch Times - August 30th, 2022 [August 30th, 2022]
- Sesame oil: Nutrition, benefits, and more - Medical News Today - August 30th, 2022 [August 30th, 2022]
- Regenerative Medicine: An alternative to surgery and pills | Loop Cayman Islands - Loop News Cayman - August 30th, 2022 [August 30th, 2022]
- Find Euphoria: the luxury Greek spa retreat to visit now - Tatler - August 30th, 2022 [August 30th, 2022]
- What Is Synthetic Urine & How Does It Help To Pass A Drug Test? - The Island Now - August 30th, 2022 [August 30th, 2022]
- The science behind the healthtech startup must be understood well - Express Healthcare - August 30th, 2022 [August 30th, 2022]
- Best-in-class second-line HIV treatment rolls out in Zambia and Nigeria - Clinton Health Access Initiative - August 30th, 2022 [August 30th, 2022]
- Therapeutic effect of HFNC and NIV in patients with AECOPD | COPD - Dove Medical Press - August 30th, 2022 [August 30th, 2022]
- Five years after Kymriah: Ensuring the next cell and gene therapies reach patients - STAT - August 30th, 2022 [August 30th, 2022]
- Meet these renowned healthcare professionals who assist us in leading healthier lives - Oneindia - August 30th, 2022 [August 30th, 2022]
- Diet and Vitiligo: The Story So Far - Cureus - August 29th, 2022 [August 29th, 2022]
- Fatphobia Sucks, Especially If You're Trying to Have a Baby - VICE - August 29th, 2022 [August 29th, 2022]
- Orthomolecular Medicine, A Predictive Tool - Nation World News - August 29th, 2022 [August 29th, 2022]
- COVID-19 vaccines and the Nuremberg Code - Science Based Medicine - August 29th, 2022 [August 29th, 2022]
- Bolstering the Blood-CNS Barrier Could Lead to New Treatment Approach for Multiple Sclerosis - University of Utah Health Care - August 29th, 2022 [August 29th, 2022]
- Lockdowns Postponed the Inevitable. Is That a Bad Thing? - Science Based Medicine - August 29th, 2022 [August 29th, 2022]
- The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review - Cureus - August 27th, 2022 [August 27th, 2022]
- Ayurveda As Alternative Medicine: Research And Development To Be Taken Ahead By Heal In India - Entrepreneur - August 27th, 2022 [August 27th, 2022]
- French Doctolib platform accused of 'promoting alternative medicine' - The Connexion - August 27th, 2022 [August 27th, 2022]
- Chronic Fatigue Syndrome: Best Ways for Treating This Condition - Healthline - August 27th, 2022 [August 27th, 2022]
- Ellen White reveals "traumatic" incident that played huge role in her retirement - GIVEMESPORT - August 27th, 2022 [August 27th, 2022]
- Curcumin and Non-Hodgkin's Lymphoma: Does It Help? - Healthline - August 27th, 2022 [August 27th, 2022]
- In Denial: When Patients Don't Want to Believe They Have Cancer - Medscape - August 27th, 2022 [August 27th, 2022]
- Piotr Szyhalski depicts living through COVID-19 and other extreme historical phenomena - MinnPost - August 27th, 2022 [August 27th, 2022]
- Researchers identify chemo alternative for targeted treatment of leukemia patients - Devdiscourse - August 27th, 2022 [August 27th, 2022]
- India Can Show The World The Right Path For Medical Pluralism - News18 - August 27th, 2022 [August 27th, 2022]
- Complementary and Integrative Medicine - Reeve Foundation - Christopher Reeve Foundation - August 23rd, 2022 [August 23rd, 2022]
- Back pain: Exploring alternative treatments - Health - Life & Style - Ahram Online - August 23rd, 2022 [August 23rd, 2022]